

Monaco

Population 2016

<1 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB) | 0 (0-0) | 0 (0-0) |
| Mortality (HIV+TB only) | 0 (0-0) | 0 (0-0) |
| Incidence (includes HIV+TB) | 0 (0-0) | 0 (0-0) |
| Incidence (HIV+TB only) | | |
| Incidence (MDR/RR-TB)** | 0 (0-0) | 0 (0-0) |

| Estimated TB incidence by age and sex (thousands)*, 2016 | | | |
|--|------------|------------|---------|
| | 0-14 years | > 14 years | Total |
| Females | 0 (-) | 0 (-) | 0 (-) |
| Males | 0 (-) | 0 (-) | 0 (-) |
| Total | 0 (-) | 0 (-) | 0 (0-0) |

| TB case notifications, 2016 | |
|--|--|
| Total cases notified | |
| Total new and relapse | |
| - % tested with rapid diagnostics at time of diagnosis | |
| - % with known HIV status | |
| - % pulmonary | |
| - % bacteriologically confirmed among pulmonary | |

| Universal health coverage and social protection | |
|--|------|
| TB treatment coverage (notified/estimated incidence), 2016 | |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | null |

| TB/HIV care in new and relapse TB patients, 2016 | | Number | (%) |
|---|--|--------|-----|
| Patients with known HIV-status who are HIV-positive | | | |
| - on antiretroviral therapy | | | |

| Drug-resistant TB care, 2016 | | | |
|---|----------------|--------------------------|-----------------|
| | New cases | Previously treated cases | Total number*** |
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | (-) |
| Estimated % of TB cases with MDR/RR-TB | 2.4% (1.6-3.2) | 11% (9.1-14) | |
| % notified tested for rifampicin resistance | | | |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | |
| Laboratory-confirmed cases | | MDR/RR-TB: , XDR-TB: | |
| Patients started on treatment **** | | MDR/RR-TB: , XDR-TB: | |

| Treatment success rate and cohort size | | |
|--|---------|--------|
| | Success | Cohort |
| New cases registered in 2015 | | |
| Previously treated cases registered in 2015 | | |
| HIV-positive TB cases registered in 2015 | | |
| MDR/RR-TB cases started on second-line treatment in 2014 | | |
| XDR-TB cases started on second-line treatment in 2014 | | |

| TB preventive treatment, 2016 | |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | |

| TB financing, 2017 | |
|------------------------------------|--|
| National TB budget (US\$ millions) | |

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB